News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
694,419 Results
Type
Article (41307)
Company Profile (402)
Press Release (652710)
Section
Business (208035)
Career Advice (1990)
Deals (35921)
Drug Delivery (85)
Drug Development (83097)
Employer Resources (168)
FDA (16251)
Job Trends (15019)
News (351206)
Policy (32949)
Tag
Academia (2617)
Africa (729)
Alliances (50495)
Alzheimer's disease (1189)
Approvals (16170)
Arizona (182)
Artificial intelligence (74)
Asia (38188)
Australia (6325)
Bankruptcy (359)
Best Places to Work (11476)
Biosimilars (64)
Biotechnology (304)
C2C Services and Suppliers (79621)
California (1952)
Canada (941)
Cancer (509)
Career advice (1659)
Cell therapy (133)
China (151)
Clinical research (64951)
Collaboration (152)
Colorado (80)
Compensation (81)
Connecticut (78)
COVID-19 (2546)
Cystic fibrosis (77)
Data (317)
Diabetes (83)
Diagnostics (6029)
Drug pricing (71)
Earnings (84859)
Employer resources (143)
Europe (83058)
Events (111207)
Executive appointments (157)
FDA (16480)
Florida (267)
Funding (154)
Gene therapy (104)
GLP-1 (543)
Government (4374)
Healthcare (18938)
Hotbed/Location (488248)
Illinois (264)
Indiana (148)
Infectious disease (2575)
Inflammatory bowel disease (97)
Interviews (305)
IPO (16476)
Job creations (3688)
Job search strategy (1423)
Kansas (96)
Layoffs (420)
Legal (7905)
Lung cancer (114)
Manufacturing (87)
Maryland (406)
Massachusetts (1624)
Medical device (13192)
Medtech (13197)
Mergers & acquisitions (19305)
Metabolic disorders (264)
Michigan (124)
Minnesota (221)
Neuroscience (1342)
New Jersey (593)
New York (607)
NextGen Class of 2024 (6704)
Non-profit (4524)
North Carolina (640)
Northern California (833)
Obesity (157)
Ohio (105)
Opinion (188)
Patents (74)
Pennsylvania (585)
People (57193)
Pharmaceutical (79)
Phase I (20305)
Phase II (28668)
Phase III (21249)
Pipeline (113)
Postmarket research (2583)
Preclinical (8703)
Press Release (67)
Rare diseases (139)
Real estate (5988)
Recruiting (64)
Regulatory (21623)
Research institute (2398)
Resumes & cover letters (348)
South America (1099)
Southern California (775)
Startups (3744)
Texas (250)
United States (8881)
Vaccines (489)
Washington State (264)
Weight loss (140)
Date
Today (101)
Last 7 days (654)
Last 30 days (2505)
Last 365 days (38229)
2024 (26990)
2023 (41013)
2022 (52276)
2021 (56766)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33026)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
694,419 Results for "panbela therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announces an oral presentation at the Digestive Disease Week conference, which was held May 18-21, 2024.
June 10, 2024
·
8 min read
Drug Development
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
Panbela Therapeutics, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
June 24, 2024
·
9 min read
BioMidwest
Panbela Announces Transfer to OTCQB Market
Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that its common stock has been approved for quotation on the OTCQB market.
April 16, 2024
·
7 min read
Business
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024.
May 1, 2024
·
6 min read
Business
Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024
May 15, 2024
·
13 min read
BioMidwest
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial’s lower-than-expected event rate suggests improved survival outcomes
Panbela Therapeutics, Inc. today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
April 22, 2024
·
8 min read
Policy
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149.
May 6, 2024
·
7 min read
BioMidwest
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”) today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
March 12, 2024
·
6 min read
Business
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.
March 26, 2024
·
14 min read
BioMidwest
Panbela Announces Poster Presentation at American Association for Cancer Research:Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer announces a poster presentation highlighting the results for ivospemin as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research, which took place April 10, 2024.
April 18, 2024
·
8 min read
1 of 69,442
Next